TG4001
Phase 2Biologic
TG4001 is one of 19 biologic programs targeting Phase IB. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
19 competitors in Phase IB
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 2
Ibrance
PfizerPhase 2
Afinitor
NovartisPhase 2
Kisqali
NovartisPhase 2
Verzenio
Eli LillyPhase 2
Bavencio
EMD SeronoPhase 2
Lisaftoclax
Ascentage Pharma Group Inc.Phase 2
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
R-CHOP
IIncyte Biosciences Japan GK
Phase 2
POLA-R-CHP
FFudan University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TG4001. EMBL-EBI & Wellcome Sanger Institute.
- [4]